Core Insights - WuXi Biologics emphasizes its commitment to sustainability and responsible water management practices on World Water Day, aiming to reduce environmental impact through efficient water use [1][2] Water Management Achievements - The company has been recognized on the CDP Water Security "A List" for three consecutive years, highlighting its industry-leading performance in environmental stewardship and transparency [2] - WuXi Biologics set a target to reduce water consumption intensity by 30% by 2025, achieving this goal by the end of 2025, demonstrating its commitment to water stewardship [3] Water Excellence Stewardship Program - In 2024, WuXi Biologics launched the Water Excellence Stewardship (WES) program to enhance site-specific water management, covering governance, balance, quality, and hygiene [4] - By the end of 2025, the WES program was implemented at 10 global sites, allowing for performance assessment and alignment with international best practices [4] Leadership and Recognition - Dr. Chris Chen, CEO of WuXi Biologics, emphasizes the importance of natural resources in biologics research and production, advocating for sustainability and responsible practices [5] - The company has received multiple recognitions for its sustainability efforts, including ratings from CDP, MSCI, EcoVadis, and inclusion in various sustainability indices [5] Company Overview - WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) providing end-to-end solutions for biologics [6] - The company employs over 12,000 skilled professionals across multiple countries and supports 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing as of December 31, 2025 [7] Commitment to Sustainability - WuXi Biologics views sustainability as essential for long-term growth, driving green technology innovations and fostering positive social and environmental impacts [8]

Core Viewpoint - WuXi Biologics has been recognized with "A" ratings by CDP for both Climate Change and Water Security in 2025, highlighting its commitment to environmental stewardship and transparency [1] Climate Change Leadership - The "A" rating for Climate Change reflects WuXi Biologics' strong environmental performance and its validated integrated climate change strategy, aiming for net-zero emissions across its value chain by 2050 [2] - The company has implemented initiatives such as energy efficiency programs, process optimization, and renewable energy adoption, with its biologics facility in Ireland operating on 100% renewable electricity [2] Water Security Excellence - WuXi Biologics has achieved a place on the CDP Water Security "A" List for the third consecutive year, demonstrating its commitment to sustainable water management [3] - The company aims to reduce water consumption intensity by 30% by the end of 2025 compared to a 2019 baseline and has launched a Water Excellence Stewardship program covering various aspects of water management [3] Supplier Engagement - Earlier in the year, WuXi Biologics received an "A" rating in the CDP's Supplier Engagement assessment, recognizing its efforts to drive climate action across its value chain [4] - The company collaborates with global suppliers to promote a sustainable economy through a comprehensive supply chain management system and Scope 3 emissions tracking [4] Leadership Commentary - Dr. Chris Chen, CEO of WuXi Biologics, expressed pride in receiving the "A" ratings, reinforcing the company's commitment to sustainability and its role as a leader in green biologics [5] Industry Recognition - WuXi Biologics has received multiple accolades for its sustainability efforts, including an MSCI AAA Rating, EcoVadis Platinum Medal, and recognition in various sustainability indices [5] Company Overview - WuXi Biologics is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) providing end-to-end solutions for biologics [6] - The company employs over 12,000 skilled professionals across multiple countries and supports 864 integrated client projects, including 24 in commercial manufacturing as of June 30, 2025 [7] Commitment to Sustainability - The company views sustainability as essential for long-term growth and continuously innovates in green technology to provide advanced CRDMO solutions [8]

Core Insights - WuXi Biologics has signed a strategic Memorandum of Understanding (MoU) with the Qatar Free Zones Authority (QFZ) to expand its global network and capabilities into the Middle East [1][3]. Company Overview - WuXi Biologics is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) that provides end-to-end solutions for the discovery, development, and manufacturing of biologics [5][6]. - The company employs over 12,000 skilled professionals across various countries, including China, the United States, Ireland, Germany, and Singapore [6]. Strategic Collaboration - The MoU facilitates the establishment of WuXi Biologics' first integrated CRDMO center in the Middle East, aiming to enhance Qatar's biotechnology sector and create a robust biopharmaceutical ecosystem [3][4]. - This partnership combines WuXi Biologics' expertise in complex biologics with Qatar's strategic vision for biopharmaceutical advancement, fostering innovation and growth [3][4]. Leadership Statements - Dr. Chris Chen, CEO of WuXi Biologics, emphasized that this partnership marks a significant step in extending the company's global capabilities and contributing to the biopharmaceutical ecosystem in Qatar [4]. - H.E. Sheikh Mohammed Bin Hamad Bin Faisal Al-Thani, CEO of QFZ, highlighted that the collaboration strengthens Qatar's position as a reliable hub for biopharmaceutical growth, leveraging WuXi Biologics' global expertise [4]. Sustainability Commitment - WuXi Biologics prioritizes sustainability as a cornerstone of its long-term growth strategy, focusing on green technology innovations and responsible practices across its operations [8].

Core Insights - WuXi Biologics has received the AAA ESG rating from MSCI for the third consecutive year, highlighting its commitment to sustainability and strong ESG performance [1][2]. Company Performance - The AAA rating places WuXi Biologics among an elite group of companies recognized for outstanding ESG performance, particularly in climate change, product safety, human capital development, and corporate governance [2]. - The company has been actively engaged with the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative, aligning its efforts with the United Nations Sustainable Development Goals [4]. Recognition and Awards - WuXi Biologics has received multiple accolades for its sustainability efforts, including an EcoVadis Platinum Medal, inclusion in the Dow Jones Sustainability Indices, and recognition as a top-rated company by Sustainalytics for five consecutive years [5]. - The company has also been rated as Prime by ISS ESG Corporate Rating and is a constituent of the FTSE4Good Index Series [5]. Operational Overview - WuXi Biologics employs over 12,000 skilled employees across various countries, including China, the United States, Ireland, Germany, and Singapore, providing efficient and cost-effective biologics solutions [8]. - As of June 30, 2025, the company is supporting 864 integrated client projects, with 24 in commercial manufacturing [8]. Commitment to Sustainability - The company views sustainability as a cornerstone of long-term business growth and continuously drives green technology innovations to offer advanced Green CRDMO solutions [9]. - WuXi Biologics collaborates with stakeholders to foster positive social and environmental impacts, promoting responsible practices throughout the value chain [9].

Core Insights - WuXi Biologics has been awarded "CDMO of the Year – Asia Pacific", "Best Biologics CDMO Award: Bioprocessing", and "Best Biologics CDMO in Greater China Region" at the APBCEA 2025 [1][2] - The company has received multiple awards since 2017, highlighting its consistent excellence in the biomanufacturing sector [1][2] Company Achievements - WuXi Biologics has a portfolio of 864 integrated projects, including 168 bispecific and multispecific antibodies and 225 antibody-drug conjugates (ADCs) [3] - The development cycle for monoclonal antibody projects has been reduced to 6 months from DNA to Investigational New Drug (IND) application [3] - The company has achieved a 100% success rate in Pre-License Inspections (PLI) and has passed 44 inspections by global regulatory authorities, including 22 by the FDA and EMA [3] Leadership and Vision - Dr. Chris Chen, CEO of WuXi Biologics, emphasized the recognition received from clients and the industry, attributing it to the company's commitment to excellence and world-class quality standards [4] - The company aims to empower partners to accelerate the delivery of groundbreaking therapies to patients globally [4] Workforce and Global Presence - WuXi Biologics employs over 12,000 skilled professionals across China, the United States, Ireland, Germany, and Singapore [6] - The company supports 864 integrated client projects, with 24 currently in commercial manufacturing as of June 30, 2025 [6] Sustainability Commitment - WuXi Biologics prioritizes sustainability as a cornerstone for long-term growth, focusing on green technology innovations and responsible practices [7] - The company collaborates with stakeholders to create positive social and environmental impacts while promoting excellence in Environment, Social, and Governance (ESG) [7]

Core Insights - WuXi Biologics has been recognized on the CDP's A List for Supplier Engagement Assessment, highlighting its leadership in climate-related supply chain engagement [1][2] - The company has achieved a 30% reduction in GHG emissions intensity (Scope 1 and Scope 2) in 2024 compared to the base year 2020, with a goal of net-zero emissions by 2050 [3][4] - WuXi Biologics has received multiple recognitions for its sustainability efforts, including an MSCI AAA Rating and inclusion in the Dow Jones Sustainability Indices [4][9] Company Overview - WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end solutions for biologics [6][8] - The company employs over 12,000 skilled professionals across various countries, supporting 817 integrated client projects as of December 31, 2024 [8] - Sustainability is a cornerstone of WuXi Biologics' long-term business strategy, focusing on green technology innovations and responsible practices [9] Environmental Commitment - WuXi Biologics is committed to the Science Based Target initiative (SBTi) and has established measurable targets for climate change [3] - The company actively engages with suppliers to enhance sustainable supply chain management and Scope 3 emissions reporting [3][4] - WuXi Biologics has been recognized for its water security efforts, being included in CDP's Water Security A List [2][4] Recognition and Ratings - The company has received leadership-level scores from CDP for two consecutive years, reflecting its commitment to climate change initiatives [2][4] - WuXi Biologics has been awarded an EcoVadis Platinum Medal and recognized as a top-rated company by Sustainalytics for five consecutive years [4][9] - The company is a participant in the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative, further emphasizing its dedication to sustainability [4]